From November 5 to 10, the 7th China International Import Expo (CIIE) was held in Shanghai. As a globally leading pharmaceutical company, GSK China participated in the CIIE once again with several key products and highlight activities, working together to build a healthier future.
At the CIIE, GSK showcased its innovative posture, bringingMultipleHeavyweight Vaccine Products Continue to Debut. At the same time, enterprisesActively Collaborate with Multiple Parties to Promote Disease Awareness Education, andJointly carried out by the media and experts from multiple fieldsFinished"Deepen the integration of medical treatment and prevention,""Building a Healthy China Together" Roundtable Forum, actively exploring innovative models of medical prevention integration to promoteChinaContribute to the construction of the vaccine prevention system. During the same period, GSKParticipated in2024 CIIE Public Health Forum, with allMultiple Partners Collaborate to Stimulate New Quality Productivity, Discussing the Development of Healthy Cities and Public Health Integration in the Greater Bay Area.
Multiple HeavyweightsProductParticipate in exhibitions
The vaccine is GlaxoSmithKline (GSK）Core BusinessOne ofSince the beginning of this year, GSK has actively responded to the call of "Healthy China Action" and "Prevention First, Combination of Prevention and Treatment". In line with the innovative models of medical prevention integration in various regions, GSK has promoted disease and vaccine science popularization education. On the basis of enhancing the awareness of vaccination, it has further promoted the innovation and accessibility of vaccines.
At this year's CIIE booth, GSK showcased several重磅 vaccine products.ContinueDebut，Among themIncludingRecombinant Zoster Vaccine (RZV) Shingrix, Imported Bivalent Human Papillomavirus (HPV) Vaccine Cervarix。Currently，Benefiting from the Spillover Effects of the CIIE,The aforementioned productsHas achieved commercialization in China.
According to Li Weidong, Vice President of GSK and head of China's vaccine business,Between the two products,Recombinant Zoster Vaccine ShingrixShingrix, which has won the Galien Award three times, known as the "Nobel Prize of the pharmaceutical industry," effectively fills the gap in the prevention of shingles in China and further expandsIn ChinaThe Vaccine Prevention System.The imported bivalent HPV vaccine, Cervarix, is currently the only HPV vaccine that uses an innovative adjuvant system, designed to provide health protection for eligible women. This innovative adjuvant system is based on the 2011 Nobel Prize in Physiology or Medicine research findings.
Li Weidong stated that thanks to the spillover effects of the CIIE, Shingrix quickly completedFinishedCommercial implementation, which is crucial for reducing the incidence of shingles and improvingMiddleThe health level and quality of life of the elderly, promoting healthy agingProviding significant assistance。May 2022，Two-dose schedule for girls aged 9-14HPVVaccineVaccination ProcedureAlso in ChinaApproved,Reflects China'sImplement prevention as the priority,Expected to boost ChinaThe early realization of the action and goals to eliminate cervical cancer.
As a leader in innovative vaccines, GSK demonstrates a strong innovative capability. Currently,GSK has 1/4 of its R&D pipeline dedicated to vaccines, with over 20 vaccine candidates in development and registration stages, covering Respiratory Syncytial Virus (RSV) vaccines, Meningococcal vaccines, and Pneumococcal vaccines, among others.。GGSK is committed to providing safe and effective vaccines for all people throughout their entire life cycle, continuously exploring more possibilities in the field of vaccines and offering innovative preventive solutions in more areas.
On the other hand, GSK is also committed to the development of adjuvant technology, applying innovative adjuvant systems to several blockbuster vaccine products to help stimulate a stronger and broader immune response, thereby maintaining high and long-lasting antibody levels. Additionally, adjuvants can reduce the amount of antigen required per dose of vaccine, thereby enabling the production of more doses to provide to more people.
Advance Medical-Preventive Integration with Multiple Parties
At the 7th China International Import Expo, GSK (GSK）StillHostFinishedMedia Roundtable Event on "Deepening the Integration of Medical Treatment and Prevention, Building a Healthy China Together." Experts from multidisciplinary fields, public health professors, representatives of grassroots medical institutions, and others attended to jointly discuss how to coordinate multi-party resources and advantages under the innovative system of integrating medical treatment and prevention, helping to safeguard public health.
Vice President of GSK,Li Weidong, Head of China Vaccine BusinessInSpeechCNSaid: "The CIIE contributes to the joint construction of 'Medical-Prevention Integration' for healthKangshengThe international dialogue and exchange platform for a state system and shared healthy future. GSK, as a global leading biopharmaceutical company, has a century-long heritage in vaccine research and development. We always remember our commitment to 'rooting in China, partnering with China, and serving China'. Focusing on innovation, we continue to deepen our presence in the Chinese market alongside local partners, enhancing vaccine accessibility and providing lifelong health protection for the public.”
Li Weidong inThe aforementioned speech also mentioned, "In the future, GSK will continue to advance vaccines.ProductInnovation, to boost the implementation and application of innovative vaccine prescription models, putting ‘the integration of medical treatment and prevention, with prevention first’ into practice, and continuously contributing to China."Bring a more positive health impact to the public in China and contribute to the advancement of the Healthy China Initiative."
Vaccination is an economically effective and positive means of preventing diseases and maintaining health. To further improve the convenience of vaccination and patient accessibility, 13 provinces/municipalities in China, including Shanghai, Guangdong, Hubei, Zhejiang, Shandong, and Chongqing, are actively exploring integrated medical-prevention models with local characteristics. Pilot programs have been launched where general practitioners issue vaccine prescriptions or health prescriptions.
Previously,Li Weidong has also expressed multiple times,GSK is not only an advocate of the integration of medical treatment and prevention, but also an active practitioner of it. In recent years, GSK has actively participated in the integration of medical treatment and prevention at different levels. As a company, GSK hopesJoining hands with multiple parties, toVaccine PrescriptionAsThe entry point is to truly implement the integration of medical treatment and prevention, and contribute to improving the widespread accessibility of Chinese vaccines.
Li Weidong believes, how to truly benefit the common people from the perspective of enterprisesAs for，BesidesProvide high-qualityIn addition to innovative products,Engage in conversations with multiple parties,AssistBuildMore PerfectVaccination System for PreventionAppears particularly crucial，TherebyEnhance the convenience of vaccination and patient accessibility in China.GSK is paying attention to the vaccine prescription policy andJoin Hands with Multiple Parties to Provide SupportOne of the enterprises，HopeTo raise public awareness on the importance of vaccine prescription, Contributing to Healthy ChinaIn-depth Development。
In"Deepening the Integration of Medical Treatment and Prevention, Building a Healthy China Together" Media Roundtable Event，Sheng Fei, Director of the Community Health Service Center in Nanxiang Town, Jiading District, Shanghai, said: "It is essential to fully leverage the important role of grassroots doctors (especially general practitioners and family doctors) in disease prevention, promote the pilot implementation of vaccination health prescriptions, and enhance...ChinaVaccination rates to achieve the national "Healthy China 2030" strategy centered on health. As an important part of accessing nearby medical services, grassroots healthcare institutions are essential to practicingThe best place for the integration of medical treatment and prevention, and also a key factor in helping adults (especially middle-aged and elderly people) strengthen disease prevention and control, and enhance their sense of health achievement.”
Rooted in China, Partnering with China, Serving China
With a broad market outlook and favorable policies, China provides fertile ground for the development of foreign enterprises. As one of GSK's most important strategic markets, GSK always remembers its commitment to "Rooted in China, Partner with China, Serve China". It is actively accelerating its layout in the Chinese market, especially in the vaccine field, striving to bring full life-cycle health protection to the public.
Currently，ChinaFacingThe two core health challenges: aging population and high incidence of chronic diseases. At the same time,The high incidence of cardiovascular and cerebrovascular diseases, diabetes, and other chronic diseases will be a long-term public health challenge that China will face in the future. In particular, patients with chronic diseases are more susceptible to infectious diseases such as influenza, pneumonia, and shingles.In 2019, the National Health Commission of China released "Core Information for the Prevention of Elderly Disability," recommending that elderly people regularly receive pneumococcal vaccine, herpes zoster vaccine, and influenza vaccine.
In addition,For patients with chronic obstructive pulmonary disease (COPD),GOLD 2024(The Global Initiative for Chronic Obstructive Pulmonary Disease Diagnosis, Treatment, and Prevention) clearly states that patients with chronic obstructive pulmonary disease should receive all vaccines recommended by local guidelines, such as influenza vaccine, pneumococcal vaccine, diphtheria-tetanus-pertussis vaccine, respiratory syncytial virus vaccine, herpes zoster vaccine, etc.
In order to further promotePublicCognition and Action on Vaccine-Preventable Diseases，FromSince 2021, GSK has supported the "Community-Based..." initiative launched by the Shenzhen Medical Association Public Welfare Foundation.Public Education Pilot Project on Hospital and Elderly Health Management Services in the Greater Bay Area (Shenzhen): During the project, general practitioners obtained vaccine prescription qualifications through training, while also helping to popularize knowledge about related diseases and prevention.
In addition, GGSK Collaborates with Media and Other Partners to Carry Out Various Science Education Initiatives, Kicking Off the Year with a Guinness World Record Event at Guangzhou Tower"Challenges" and other herpes zoster disease science popularization activities continue to strengthen public awareness and prevention consciousness of the disease, making adult vaccines one of the hot topics in the industry.
For many years,GGSK Centers on Patients, and Through the Innovative Strategies of “China First” and “Tailor-Made,” Taps into the Medical Market Needs in China to Advance Disease Prevention and Vaccine Accessibility. GSK Will Continue to Enhance Local Communication and Cooperation, Adhere to a Science-Driven Approach, Focus on the Core of Innovation, Deeply Cultivate the Chinese Market, and Continuously Improve the Accessibility and Affordability of Quality Healthcare Resources., joining hands with multiple partners to promotePublicCognition and Action on Vaccine-Preventable Diseases
Outside the CIIE,This year, GSK joined hands with the School of Medicine at Tsinghua University to delve into infectious disease research, integrating industry and academia. Together, they explored how to use new technologies to promote the transformation of innovative achievements in the field of infectious diseases, helping to address unmet medical needs in China's infectious disease sector.In the future,GSKAlsoWill continue to bring more innovative products to Chinese consumers, while expanding the vaccine portfolio and enhancing vaccine accessibility, continuously creating a more positive health impact for Chinese patients and consumers.
